GleamWall
中文EN

VSBC VITASPRING BIOMEDICAL CO. LTD.

Services-Commercial Physical & Biological Research · OTC · SEC CIK 1697884 · Fiscal year ends 01/31

Financial factors as of 2026-07-31 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY14.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-2,861.9%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets31,554.8%
Debt / equity—
Current ratio0.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.02x
Accruals ratio-2,928.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-07-312027Q12026-04-302026Q4*2026-01-312026Q32025-10-312026Q22025-07-312026Q12025-04-302025Q4*2025-01-312025Q32024-10-31
Income statement
Revenue$0$0$0$0$0$0$0$0
SG&A expense$5,830$75,844$81,464$135,733$6,054$69,147$48,129$117,927
Operating income-$161,817-$75,844-$81,464-$135,733-$99,067-$69,147-$48,129-$117,927
Pretax income-$155,817-$75,844-$81,464-$135,733-$99,067-$69,147-$48,129-$117,927
Income tax$0$0$0$6,785$11,778$11,394$95,008$78,365
Net income-$155,817-$75,844-$81,464-$142,518-$110,845-$80,541-$143,137-$196,292
EBITDA-$160,157-$73,355-$78,975-$133,244-$96,577-$66,658-$45,640-$115,438
EPS (diluted)0.000.00—0.000.000.00—0.00
Weighted avg. shares (diluted)207.03M207.03M—207.03M207.03M207.03M—207.03M
Balance sheet
Cash & equivalents$13,367$8,167$2,084$0$799$0$272$2,062
Receivables——————$0$0
Current assets$14,822$9,772$10,527$9,827$7,893$295$272$41,787
PP&E, net$0$1,660$4,149$6,638$9,127$11,617$14,106$16,595
Total assets$14,822$11,432$14,676$16,465$17,020$11,912$14,378$58,382
Current liabilities$2.27M$4.52M$4.45M$4.37M$4.22M$4.11M$4.03M$3.93M
Total liabilities$4.68M$4.52M$4.45M$4.37M$4.22M$4.11M$4.03M$3.93M
Shareholders' equity-$4.66M-$4.51M-$4.43M-$4.35M-$4.21M-$4.10M-$4.02M-$3.87M
Shares outstanding207.03M207.03M207.03M207.03M207.03M207.03M207.03M—
Cash flow statement
Operating cash flow$5,200$6,083$124-$839-$1,186-$787-$1,790-$6,441
Financing cash flow$0$0$0$2,000$1,985$515$0$2,978
Depreciation & amortization$1,660$2,489$2,489$2,489$2,490$2,489$2,489$2,489
Stock-based compensation——$0$0$0$0$0$27,478

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.